416 related articles for article (PubMed ID: 35062322)
1. Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors.
Hong B; Sahu U; Mullarkey MP; Kaur B
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062322
[TBL] [Abstract][Full Text] [Related]
2. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
[TBL] [Abstract][Full Text] [Related]
3. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
[TBL] [Abstract][Full Text] [Related]
4. In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV.
Jahan N; Ghouse SM; Martuza RL; Rabkin SD
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578321
[TBL] [Abstract][Full Text] [Related]
5. The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1.
Kalke K; Orpana J; Lasanen T; Esparta O; Lund LM; Frejborg F; Vuorinen T; Paavilainen H; Hukkanen V
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746761
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic herpes simplex virus and immunotherapy.
Ma W; He H; Wang H
BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
[TBL] [Abstract][Full Text] [Related]
7. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
[TBL] [Abstract][Full Text] [Related]
8. Tumor Tropism of DNA Viruses for Oncolytic Virotherapy.
Enow JA; Sheikh HI; Rahman MM
Viruses; 2023 Nov; 15(11):. PubMed ID: 38005938
[TBL] [Abstract][Full Text] [Related]
9. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
Kahramanian A; Kuroda T; Wakimoto H
Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
Ghonime MG; Cassady KA
Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
[TBL] [Abstract][Full Text] [Related]
11. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
Menotti L; Avitabile E
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
[TBL] [Abstract][Full Text] [Related]
12. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
13. Identification of Rab27a as a host factor for oncolytic herpes virus susceptibility to tumor cells.
Zhou X; Zhao J; Wu Y; Wang L; Ji D; Chen X; Ren P; Zhou GG
Virus Res; 2021 Jul; 299():198425. PubMed ID: 33905773
[TBL] [Abstract][Full Text] [Related]
14. Human Monocytes Are Suitable Carriers for the Delivery of Oncolytic Herpes Simplex Virus Type 1 In Vitro and in a Chicken Embryo Chorioallantoic Membrane Model of Cancer.
Reale A; Krutzke L; Cadamuro M; Vitiello A; von Einem J; Kochanek S; Palù G; Parolin C; Calistri A
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298206
[TBL] [Abstract][Full Text] [Related]
15. Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.
Passer BJ; Wu CL; Wu S; Rabkin SD; Martuza RL
Gene Ther; 2009 Dec; 16(12):1477-82. PubMed ID: 19693098
[TBL] [Abstract][Full Text] [Related]
16. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.
Lee TJ; Nair M; Banasavadi-Siddegowda Y; Liu J; Nallanagulagari T; Jaime-Ramirez AC; Guo JY; Quadri H; Zhang J; Bockhorst KH; Aghi MK; Carbonell WS; Kaur B; Yoo JY
Mol Cancer Ther; 2019 Jun; 18(6):1127-1136. PubMed ID: 30926634
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.
Kang KD; Bernstock JD; Totsch SK; Gary SE; Rocco A; Nan L; Li R; Etminan T; Han X; Beierle EA; Eisemann T; Wechsler-Reya RJ; Bae S; Whitley R; Gillespie GY; Markert JM; Friedman GK
Clin Cancer Res; 2022 Dec; 28(24):5419-5430. PubMed ID: 36239623
[TBL] [Abstract][Full Text] [Related]
18. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.
Li H; Nakashima H; Decklever TD; Nace RA; Russell SJ
Cancer Gene Ther; 2013 Aug; 20(8):478-85. PubMed ID: 23868101
[TBL] [Abstract][Full Text] [Related]
19. Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.
Cuddington BP; Mossman KL
J Virol; 2014 Jun; 88(12):6885-95. PubMed ID: 24696490
[TBL] [Abstract][Full Text] [Related]
20. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
[No Abstract] [Full Text] [Related]
[Next] [New Search]
